Y-mAbs Therapeutics Inc (YMAB, Financial) is set to release its Q3 2024 earnings on Nov 8, 2024. The consensus estimate for Q3 2024 revenue is $23.26 million, and the earnings are expected to come in at -$0.16 per share. The full year 2024's revenue is expected to be $91.67 million and the earnings are expected to be -$0.64 per share. More detailed estimate data can be found on the Forecast page.
Y-mAbs Therapeutics Inc (YMAB, Financial) Estimates Trends
Over the past 90 days, revenue estimates for Y-mAbs Therapeutics Inc (YMAB) have declined from $94.48 million to $91.67 million for the full year 2024 and from $115.3 million to $110.2 million for 2025. Earnings estimates have also seen adjustments; for the full year 2024, estimates have declined from -$0.54 per share to -$0.64 per share, while for 2025, estimates have improved from -$0.72 per share to -$0.56 per share.
Y-mAbs Therapeutics Inc (YMAB, Financial) Reported History
In the previous quarter of June 30, 2024, Y-mAbs Therapeutics Inc's (YMAB) actual revenue was $22.8 million, which missed analysts' revenue expectations of $23.019 million by -0.96%. Y-mAbs Therapeutics Inc's (YMAB) actual earnings were -$0.21 per share, which missed analysts' earnings expectations of -$0.15 per share by -40%. After releasing the results, Y-mAbs Therapeutics Inc (YMAB) was down by -11.24% in one day.
Y-mAbs Therapeutics Inc (YMAB, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 10 analysts, the average target price for Y-mAbs Therapeutics Inc (YMAB) is $20.80 with a high estimate of $26 and a low estimate of $11. The average target implies an upside of 32.65% from the current price of $15.68.
Based on GuruFocus estimates, the estimated GF Value for Y-mAbs Therapeutics Inc (YMAB, Financial) in one year is $15.74, suggesting an upside of 0.38% from the current price of $15.68.
Based on the consensus recommendation from 10 brokerage firms, Y-mAbs Therapeutics Inc's (YMAB, Financial) average brokerage recommendation is currently 2.1, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
